Business
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for areas with high unmet medical need.
AbCellera revenue jumped and losses narrowed, but cash burn persisted and the accounting screen is weak.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage antibody medicines platformNote
- Revenue — Revenue +160.6% to $75.1MOK
- Profitability — Net loss narrowed to $146.4MOK
- Cash quality — Free cash flow still -$174.1MWatch
- Capital — Capex -45.4% to $42.8MOK
- Insiders — 4 buys / 0 sells; $1.04M totalOK
- Accounting — Altman-Z distress; revenue audit focusWatch
Where the revenue comes from
Fiscal 2025, as AbCellera Biologics Inc. reports it. History and quarterly detail are in the app.
- Licensing and royalty revenue$46.9M
- Research fees$27.2M
- Milestone payments$1.0M
Leadership changes
From AbCellera Biologics Inc.'s own filings, the day they're filed.
- Lynn Seely · director · departureeff. 2026-06-30
- Victor Sandor · director · departureeff. 2026-06-01
- Stephen Quake · director · departureeff. 2025-11-10
Latest filings
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AbCellera Biologics Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.